Keytruda + Avastin + chemo for ovarian cancer with minimal remaining disease
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have high-grade ovarian cancer (not mucinous or low-grade).
- You must have finished at least 6 cycles of standard platinum and taxane chemotherapy (with or without Avastin) and have minimal residual disease—either found during a second-look surgery or through a special blood test called Signatera.
- You must not have been treated with immunotherapy (like Keytruda) before, and you must not have a known BRCA mutation or HRD positive tumor.
- You need to have good organ function (kidneys, liver, blood counts) and be generally healthy (able to do daily activities with little help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.